Cancer Communications (Aug 2023)
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
Abstract
No abstracts available.
Cancer Communications (Aug 2023)